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Anticoagulation with unfractionated heparin is used for
complex operations on the thoracic aorta both as a standard
regimen for vascular procedure and as an anticoagulant for
partial femorofemoral cardiopulmonary bypass. With repeat-
ed exposure to unfractionated heparin, heparin-induced
thrombocytopenia, a severe antibody-mediated drug reaction,
may develop in some patients who have previously received
heparin. Most patients have only isolated thrombocytopenia,
a complication that usually does not cause major morbidity.
Paradoxically, a subset of patients with thrombocytopenia
will have thrombotic or thromboembolic complications, pos-
sibly because of in vivo platelet activation. The heparin-to-
heparin body complexes stimulate platelets with subsequent
platelet aggregation, disseminated thrombosis, and embolism
with platelet-rich, fibrinolysis-resistant clots.1 Most episodes
of heparin-induced thrombocytopenia are caused by an
immunoglobulin G antibody that forms after several days of
exposure to heparin. The immunoglobulin G interacts with
heparin and the platelet surface to cause activation of
platelets. Platelet factor 4 is a necessary cofactor in this dis-
ease. It combines with heparin to form a complex to which
the heparin-induced platelets bind to platelet factor 4 when
platelet factor 4 is complexed with heparin but does not bind
to heparin alone.2 If heparin-induced thrombocytopenia is
detected before the operation, anticoagulation with heparin
for vascular surgery or cardiopulmonary bypass is precluded
and an alternative anticoagulant should be used.3
In this report we describe the cases of 2 patients with
heparin-induced thrombocytopenia after multiple previous
cardiac procedures who successfully underwent extended
operations on the aortic arch and descending thoracic aorta.
Anticoagulation for cardiopulmonary bypass was performed
with recombinant hirudin, a direct thrombin inhibitor.
Clinical summaries. The first patient, a 64-year-old man
with depressed left ventricular function (left ventricular ejec-
tion fraction of 0.30) and a history of composite graft replace-
ment of the ascending aorta 8 years previously because of
acute aortic dissection, was admitted to our institution
because of symptomatic aneurysm of the distal part of the
aortic arch and the entire descending thoracic aorta with a
maximal diameter of 70 mm. After cardiac catheterization, a
thrombocytopenia with a platelet count of 60,000 cells/mm3
developed. The diagnosis of heparin-induced thrombocytope-
nia type II was confirmed by heparin-induced thrombocyte
activation assay. The patient underwent replacement of the
distal part of the aortic arch and descending thoracic aorta
with partial femorofemoral cardiopulmonary bypass and
hirudin as anticoagulant. The postoperative amount of
drained blood was 850 mL. In total he received 4 units of ery-
throcyte concentrates and 6 units of fresh-frozen plasma. The
postoperative course was completely uneventful.
The second case was that of a 68-year-old patient with dif-
fuse atherosclerosis and a history of a Y-graft replacement of
the infrarenal aorta as a result of an aneurysm some 15 years
before, left-sided carotid endarterectomy performed 12 years
previously, and combined coronary artery bypass grafting
and a right-sided carotid endarterectomy performed 5 years
before. Cardiac catheterization performed because of recur-
rent angina pectoris demonstrated progressive atherosclerotic
disease of a graft to the left anterior descending coronary
artery and of the native vessels, aortic valve stenosis with a
mean gradient of 53 mm Hg, and a left ventricular ejection
fraction of 0.30. The additional finding was an aneurysmal
dilation of the descending thoracic aorta with a maximal
diameter of 60 mm. After cardiac catheterization, progressive
thrombocytopenia developed; this improved with heparin
withdrawal. Heparin-induced thrombocytopenia type II was
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Fig 1. Recombinant hirudin concentration online-measured
by ecarin clotting time (TAS-ECT) and activated clotting time
(ACT) during cardiopulmonary bypass.
diagnosed by heparin-induced thrombocyte activation assay.
The patient underwent combined reoperative coronary artery
bypass grafting and aortic valve replacement. The operation
was performed with recombinant hirudin as an anticoagulant
for cardiopulmonary bypass. Two weeks after an uneventful
operation and postoperative course he underwent an emer-
gency operation because of rupture of the already known
descending thoracic aneurysm. Total replacement of the
descending thoracic aorta was performed with partial femo-
rofemoral cardiopulmonary bypass and recombinant hirudin
as an anticoagulant. He received in total 5 units of erythrocyte
concentrates and 4 units of fresh-frozen plasma. The postop-
erative bleeding through the chest tube was 570 mL. The
operation and the postoperative course were uneventful.
The same anticoagulant protocol was applied in both cases,
as follows. Initially, recombinant hirudin (0.25 mg/kg body
weight) was given intravenously as a bolus. Additional
recombinant hirudin was given in the priming volume of the
cardiopulmonary bypass at a dose of 0.20 mg/kg of body
weight.4 The levels of recombinant hirudin were measured in
citrated whole blood with the TAS analyzer (Cardiovascular
Diagnostics Inc, Raleigh, NC), and the cardiopulmonary
bypass was started when the ecarin clotting time was longer
than 400 seconds, which corresponded to a concentration of
recombinant hirudin level in citrated whole blood of more
than 4 m g/mL (Fig 1). During cardiopulmonary bypass,
boluses of 10 mg recombinant hirudin were given intra-
venously to maintain a hirudin level in whole blood between
3 and 4 m g/mL (corresponding to an ecarin clotting time of
350-400 seconds). A 2,000,000 KIU (280 mg) dose of apro-
tinin was given as a short infusion before cardiopulmonary
bypass and an additional 2,000,000 KIU aprotinin was added
to the priming solution, followed by a continuous infusion of
aprotinin at a dose of 500,000 KIU/h (70 mg/h) during car-
diopulmonary bypass. After weaning from cardiopulmonary
bypass, modified ultrafiltration was applied and a forced
diuresis was stimulated with an intravenous infusion of 20 g
mannitol, continuous infusion of dopamine (2 m g/kg of body
weight), and 40-mg boluses of furosemide. The first clots
were seen in the operating field within 30 minutes after the
cessation of cardiopulmonary bypass. The postoperative anti-
coagulation regimen consisted of continuous infusion of
recombinant hirudin to achieve a partial thromboplastin time
of about 60 seconds.
Comment. Our report shows that extended operations on
the aortic arch and descending thoracic aorta can be success-
fully performed in patients with heparin-induced thrombocy-
topenia by using recombinant hirudin as an anticoagulant.
Alternative anticoagulant treatments include warfarin,
ancrod, prostaglandins, and the heparinoid danaparoid sodi-
um (Orgaran), which has some risk of immune cross reaction.
We decided to use recombinant hirudin, a direct thrombin
inhibitor, because it possesses some important advantages
with respect to other alternatives, such as that subsequent
normal anticoagulation can be achieved early after surgery
because of its fast renal elimination (about 40 minutes in
patients with normal renal excretion). It is necessary to
emphasize that there is no antidote to hirudin and the reversal
of the drug therefore requires clearance from plasma. It
depends on normal renal function, with a rapid fall of the
concentration at the end of the operation as assessed by
means of the ecarin clotting time and plasma concentration of
recombinant hirudin.
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